This is a working overview of copper(II) centre, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-21 and is reviewed periodically as new material appears.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
| Property | Value | Notes |
|---|---|---|
| Primary identity method | Reverse-phase HPLC with mass spectrometry | Confirms peptide mass and retention behavior |
| Copper quantification | ICP-MS or atomic absorption spectroscopy | Measures metal content and stoichiometry |
| Spectroscopic feature | Visible absorption from copper(II) d-d transitions | Explains blue to blue-violet color |
| Recommended holding condition | Desiccated, protected from light, stored cold | Reduces hydrolysis, oxidation, and moisture uptake |
| Common purity check | HPLC area percent against a reference standard | Values depend on method and standard choice |
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Secondly, elements 104 and 105 were given names favored by JINR, despite earlier recognition of LBL as an equal co-discoverer for both of them. Thirdly and most importantly, IUPAC rejected the name seaborgium for element 106, having just approved a rule that an element could not be named after a living person, even though the 1993 report had given the LBL team the sole credit for its discovery. In 1995, IUPAC abandoned the controversial rule and established a committee of national representatives aimed at finding a compromise. They suggested seaborgium for element 106 in exchange for the removal of all the other American proposals, except for the established name lawrencium for element 103. The equally entrenched name nobelium for element 102 was replaced by flerovium after Georgy Flerov, following the recognition by the 1993 report that that element had been first synthesized in Dubna. This was rejected by American scientists and the decision was retracted. The name flerovium was later used for element 114. In 1996, IUPAC held another meeting, reconsidered all names in hand, and accepted another set of recommendations; it was approved and published in 1997. Element 105 was named dubnium (Db), after Dubna in Russia, the location of the JINR; the American suggestions were used for elements 102, 103, 104, and 106. The name dubnium had been used for element 104 in the previous IUPAC recommendation. The American scientists "reluctantly" approved this decision.
Analysis of an intermediate plasminogen structure suggests that plasminogen conformational change to the open form is initiated through KR-5 transiently peeling away from the PAp domain. These movements expose the KR5 lysine-binding site to potential binding partners, and suggest a requirement for spatially distinct lysine residues in eliciting plasminogen recruitment and conformational change respectively.
On 2 March, Hospital Moinhos de Vento, the largest of the hospitals within private networks in Rio Grande do Sul, had to rent a container in order to store the bodies of dead patients at the hospital, since the morgue in the hospital had also reached capacity. The collapse of the health system continued with daily records of hospitalizations in the city. In the Hospital de Clínicas, there were not enough specialized respirators. Along with this, health professionals had to choose which patients they should intubate, due to a lack of beds. Some patients went to be intubated at hospitals and would die there. At Hospital da Restinga, patients in the overcrowded emergency ward received care sitting in chairs due to the lack of stretchers. In some hospitals, some patients died in the hospital corridors due to a lack of beds. On 5 March, the state government also announced a fine of up to 4,000 real for those who did not wear masks, in an attempt to contain the spread of COVID-19. Melo, however, declared that the city would not apply the standard, saying he would not have people abide by the decision and that the usage of prevention methods would depend on the "conscience" of people. The municipality sought to disperse encampments at different points in the city, primarily in the Cidade Baixa neighborhood, considered a hotbed for petty crime and drug use. On the 10th and 14 March, two anti-government protests called for the reopening of local businesses and military intervention, respectively. They were held despite guidance against large gatherings.
Sources: en.wikipedia.org
Bucillamine is an antirheumatic agent developed from tiopronin. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties. Bucillamine is currently being investigated for COVID-19 drug repurposing. Bucillamine has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. It is a cysteine derivative with 2 thiol groups that is 16-fold more potent than acetylcysteine (NAC) as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection. Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues. Bucillamine has both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is hypothesized that similar processes related to reactive oxygen species (ROS) are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of bucillamine as an intervention for COVID-19. On July 31, 2020, the U.S. Food & Drug Administration (FDA) has approved Revive Therapeutics Ltd. to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
4-Chloromethcathinone (also known as 4-CMC and clephedrone) is a stimulant drug of the cathinone class that has been sold online as a designer drug. 4-CMC produces similar effects to mephedrone, and has been sold as an alternative in countries where mephedrone was scheduled. 4-CMC produces similar side effects to mephedrone, including: increased blood pressure, tachycardia, hyperthermia, and anxiety. Its chemical structure closely resembles para-chloromethamphetamine, raising concerns about its potential to readily induce cell death of serotonergic neurons. However, no neurotoxicity of this kind has been found to occur, but studies involving mice do indicate that it is neurotoxic through other mechanisms, similarly to other cathinones. 4-CMC is cytotoxic and induces oxidative stress, more so than 4-MMC. Moreover, β-keto substitution is thought to change cathinone structure activity relationships (SAR) and metabolism compared to amphetamines, leading to differences in pharmacology.
On March 22, 2023, Valve announced Counter-Strike 2, which utilizes the Source 2 game engine. It was originally announced as a free upgrade to Global Offensive with a summer 2023 release date. On September 1, 2023, it was released as a limited beta, and the game replaced Global Offensive on September 27.
=== A10BB Sulfonylureas === A10BB01 Glibenclamide A10BB02 Chlorpropamide A10BB03 Tolbutamide A10BB04 Glibornuride A10BB05 Tolazamide A10BB06 Carbutamide A10BB07 Glipizide A10BB08 Gliquidone A10BB09 Gliclazide A10BB10 Metahexamide A10BB11 Glisoxepide A10BB12 Glimepiride A10BB31 Acetohexamide
Sources: en.wikipedia.org
Identification usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. The copper content can be measured separately by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. The combination helps distinguish the intact complex from free peptide or free copper.
Light, oxygen, moisture, extreme pH, and elevated temperature can promote degradation or change copper coordination. Aqueous solutions are more vulnerable than dry solid because water enables hydrolysis and oxidation. Freeze-thaw cycling can also reduce sample quality.
A certificate of analysis summarizes tests performed by a supplier, but it does not guarantee that the material is suitable for every use. Methods, limits, and reporting practices differ between laboratories. Independent verification or raw data review is often needed for critical applications.
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.